News catch-up

I’ve been very busy recently and as a consequence, I’m aware that my output has been slipping somewhat, so I think a news catch-up post might be in order.

Bob Fiddaman at Seroxat Suffers has been keeping his finger well and truly on the pulse with some great stories:

In Australia, Bob has managed to get GSK adverts for Aropax (Seroxat/Paxil) removed from the website of the Delphi Centre (their strapline: Expertise you can confidently rely on!) The problem is/was, under Australian law these ads should never have been there in the first place…

In another post, Bob looks at the way GSK tried to deal with criticism of Avandia: Sen. Charles Grassley said in a Senate floor speech Wednesday (Sept. 12) he has two internal e-mails from GlaxoSmithKline showing the company tried to silence a medical researcher who suggested Avandia may have health risks beyond those stated on the label.

“Based on this e-mail exchange, it seems to me that at least two drug company officials did attempt to silence a critic,” said Grassley, ranking Republican on the Finance Committee. “In fact, Dr. Buse stopped making any critical statements about Avandia shortly after this e-mail exchange,” which is dated June 25, 1999.

You can read the whole story here at Seroxat Sufferers.

Meanwhile over at Clinical Psychology and Psychiatry: A Closer Look, CL Psych has any number of great news items.

One that stands out for me is this one: Key Opinion Leader Contradicts Himself. This story concerns our old friend Dr Chuck Nemeroff and his somewhat bizarre and contradictory views on Serotonin and the good old chemical imbalance hypothesis… I think CL Pysch has the answer to the contadictions.

The other standout piece for me is about SSRI prescribing and suicide rates in the USA. You may have read some stories a couple of weeks ago claiming that declining SSRI prescription rates have lead to an increase in suicides… ah, well, perhaps not.

CL Pysch’s post includes a link to the New York Times article that has some great reporting on the story and very some telling quotes from respected researchers that may be slightly more independent than the authors of the original study that seemed to tow the big pharma line.

Lastly CL Pysch returns to the Zyprexa debate, with a post that shows exactly how one Lilly employee thought about different ways to suppress a study’s negative results. You simply must have a look at the email where the options were discussed. Naughty. Very naughty.

I’m sure these links will keep you busy for a while…


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: